The mechanism of action of interferon-β in relapsing multiple sclerosis
about
Treatment with disease modifying drugs for people with a first clinical attack suggestive of multiple sclerosisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisImmunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysisTreatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviewsOptimizing therapeutics in the management of patients with multiple sclerosis: a review of drug efficacy, dosing, and mechanisms of actionBenefits versus risks of latest therapies in multiple sclerosis: a perspective reviewM1 and M2 immune activation in Parkinson's Disease: Foe and ally?Pathophysiological processes in multiple sclerosis: focus on nuclear factor erythroid-2-related factor 2 and emerging pathwaysCurrent and emerging therapies in multiple sclerosis: a systematic reviewTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Therapeutic Approach to the Management of Pediatric Demyelinating Disease: Multiple Sclerosis and Acute Disseminated Encephalomyelitis.Treatments for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP): an overview of systematic reviews.Spontaneous activation of RNA-sensing pathways in autoimmune disease.Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis.The role of immune cells, glia and neurons in white and gray matter pathology in multiple sclerosis.Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosisHomeostatic interferon expression in neurons is sufficient for early control of viral infectionEndogenous interferon-β-inducible gene expression and interferon-β-treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis.Interferon-β suppresses murine Th1 cell function in the absence of antigen-presenting cells.IFN-β Selectively Inhibits IL-2 Production through CREM-Mediated Chromatin Remodeling.Dynamic roles of type I and type II IFNs in early infection with Mycobacterium tuberculosis.Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosisRadiologically isolated syndrome: watchful waiting vs. active treatment.Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNß in Multiple Sclerosis Patients According to the Therapeutic Response to IFNß.Interferon-β1b increases Th2 response in neuromyelitis optica.What do effective treatments for multiple sclerosis tell us about the molecular mechanisms involved in pathogenesis?Advances in and Algorithms for the Treatment of Relapsing-Remitting Multiple SclerosisType I IFN receptor controls activated TYK2 in the nucleus: implications for EAE therapy.IFNAR signaling directly modulates T lymphocyte activity, resulting in milder experimental autoimmune encephalomyelitis development.Interferon beta and glatiramer acetate therapy.IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function.Spinal toll-like receptor signaling and nociceptive processing: regulatory balance between TIRAP and TRIF cascades mediated by TNF and IFNβ.Neuropathic pain in animal models of nervous system autoimmune diseases.Interferon-β Modulates Inflammatory Response in Cerebral IschemiaPathoetiology of multiple sclerosis: are we barking up the wrong tree?Natural killer cells and their receptors in multiple sclerosis.Intranasal Administration of Interferon Beta Attenuates Neuronal Apoptosis via the JAK1/STAT3/BCL-2 Pathway in a Rat Model of Neonatal Hypoxic-Ischemic EncephalopathyThe Brain Proteome of the Ubiquitin Ligase Peli1 Knock-Out Mouse during Experimental Autoimmune EncephalomyelitisNurses' perspective on approaches to limit flu-like symptoms during interferon therapy for multiple sclerosis.Adrenergic and dopaminergic modulation of immunity in multiple sclerosis: teaching old drugs new tricks?
P2860
Q24185806-1A851B9D-A700-4F96-B98A-ED0546167CB6Q24187126-B4CDA5C0-A059-4254-9CE0-EBBBFE77B6EEQ24188270-93639C41-75CA-41A5-82C5-4A84EAD40AFCQ24201434-1179F69C-1EB9-49E2-88B8-FCD739AEF0B3Q26822611-BAC9A89E-E38C-4AF1-A61D-4983753E04A1Q26999417-10D91857-E7D9-4B51-A188-7565F60F2AAEQ27024667-CDE64385-59C4-43AC-A267-62468E02C484Q28235168-5AF2DC44-42D0-4C63-81E3-6D15DBA94A1AQ29010983-90157CCD-E996-49F8-B45C-F11577295205Q30234672-69E5EDE9-6649-4CEE-A79C-0D29924CFF39Q30354658-FDBE0B06-E815-421A-8E3E-4FE1BC55CDF8Q30397454-488973F9-B20E-423C-AEF5-3302315A55B9Q33909504-046117E7-6A0F-42C4-A2CC-5AC79753B9FFQ34049754-497FAB99-26B3-4DAF-B0CA-01CA49F6EEE8Q34468304-C3C7B653-0E6F-46ED-A519-006025350281Q34671815-9D73A951-3F6E-4DC8-9E0F-92C888293070Q35075450-5845E850-B497-4CBB-A432-A8B49809807BQ35146806-AD2B8755-27FD-4A75-B443-232152AD651FQ35461764-C35A0FBA-C565-4C5B-B31C-6A2C910DCE09Q35613108-783B91B7-90D3-401A-9E61-22F8850004BBQ36019386-2E18211F-091C-40DA-9335-52208BE76E38Q36174813-F544164C-CCA3-43A8-81CD-B83F7FE73AF8Q36188305-04723A07-64BA-4262-9848-F23FB8190778Q36253827-B1F03401-97F0-4171-9D7B-254B46F421A5Q36396409-75F5C5B3-E1DE-40AE-98C9-971C7D468D16Q36396476-F28EC34A-90E4-4498-9A4C-A2C7C9F49926Q36484448-7E74C838-D3DB-40DB-BD2D-A46A30B6F045Q36501690-F6795546-6488-4527-B59E-5DC29FFBF523Q36509839-D03B8DFA-0E03-44B6-A3E5-DA74DBF01E90Q36568660-470F3C65-23FD-4B09-A081-B54365536B26Q36662334-77478987-9304-4269-973F-67133A8E264FQ36756027-F556F539-A52F-427E-A737-7A51EBA0C8A7Q36869524-0DF98CB4-DC04-4B9F-AE91-A66713DF220CQ36877674-FF710228-9EA7-4012-BFC8-D9D7C1A15377Q36904407-B88A9D81-3FC8-4FAF-8A87-E8A6D709A96FQ37124504-0BAA94D0-CA0A-475A-973D-5FF679FE1618Q37299279-90EE0C36-833B-44A6-B74C-7230A02726F3Q37333860-F65CE21C-340A-44EE-B4B2-BA8F432D65FAQ37668556-CC15926C-486E-4F2A-92BB-56BDA1966052Q38052870-71304E23-D242-44D3-B5F1-B1B55F4FEAA1
P2860
The mechanism of action of interferon-β in relapsing multiple sclerosis
description
2011 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունիսին հրատարակված գիտական հոդված
@hy
artículu científicu espublizáu en 2011
@ast
im Juni 2011 veröffentlichter wissenschaftlicher Artikel
@de
scientific article (publication date: June 2011)
@en
vedecký článok (publikovaný 2011/06/01)
@sk
vědecký článek publikovaný v roce 2011
@cs
wetenschappelijk artikel (gepubliceerd op 2011/06/01)
@nl
наукова стаття, опублікована в червні 2011
@uk
مقالة علمية (نشرت في يونيو 2011)
@ar
name
The mechanism of action of interferon-β in relapsing multiple sclerosis
@ast
The mechanism of action of interferon-β in relapsing multiple sclerosis
@en
The mechanism of action of interferon-β in relapsing multiple sclerosis
@nl
type
label
The mechanism of action of interferon-β in relapsing multiple sclerosis
@ast
The mechanism of action of interferon-β in relapsing multiple sclerosis
@en
The mechanism of action of interferon-β in relapsing multiple sclerosis
@nl
prefLabel
The mechanism of action of interferon-β in relapsing multiple sclerosis
@ast
The mechanism of action of interferon-β in relapsing multiple sclerosis
@en
The mechanism of action of interferon-β in relapsing multiple sclerosis
@nl
P2860
P3181
P1433
P1476
The mechanism of action of interferon-β in relapsing multiple sclerosis
@en
P2860
P304
P3181
P356
10.2165/11591110-000000000-00000
P407
P577
2011-06-01T00:00:00Z
P6179
1053715262